DDInter1676 DDInter642
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or
Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022.
Enfortumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lumacaftor
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Enfortumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Enfortumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Enfortumab vedotin may cause a minor interaction that can limit clinical effects when taken with Lumacaftor
Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Enfortumab vedotin may lead to a major life threatening interaction when taken with Fingolimod
Enfortumab vedotin may lead to a major life threatening interaction when taken with Upadacitinib